Prescribing Guidelines for Baxfendy (Baxdrostat)
Starting Dose and Titration
Start Baxfendy at 2 mg orally once daily in adults with uncontrolled hypertension on background antihypertensive therapy. 1 This is the FDA-approved starting dose for patients not adequately controlled on other agents. The drug is taken once daily at the most convenient time to establish a habitual pattern and improve adherence 2.
While clinical trials evaluated doses of 0.5 mg, 1 mg, 2 mg, and 4 mg 3, 4, the FDA label specifies 2 mg as the recommended starting dose 1. Both 1 mg and 2 mg doses demonstrated significant blood pressure reductions (placebo-corrected differences of -8.7 mmHg and -9.8 mmHg respectively) 3, but the 2 mg dose is the approved starting point.
Required Laboratory Monitoring
Check serum potassium and renal function (eGFR) before initiating Baxfendy and monitor regularly after starting treatment. 1 This is critical because:
- Baxdrostat increases serum potassium by approximately 0.39-0.47 mmol/L 5, 6
- Hyperkalemia (K+ >6.0 mmol/L) occurred in 2-3% of patients in clinical trials 3
- The drug modestly reduces eGFR by approximately 5.49 mL/min/1.73 m² 6
The FDA label mandates testing prior to and after initiation 1, though specific monitoring intervals are not detailed in the available prescribing information.
Contraindications and Critical Precautions
Absolute Contraindications
The FDA label lists specific contraindications 1, with hyperkalemia and hyponatremia highlighted as key warnings 1.
Potassium-Sparing Agents: Exercise Extreme Caution
Avoid combining Baxfendy with potassium-sparing diuretics, mineralocorticoid receptor antagonists, ACE inhibitors, ARBs, and certain immunosuppressants unless potassium is closely monitored. 7, 1 The 2025 AHA/ACC guidelines specifically warn that drugs reducing potassium excretion include:
- Potassium-sparing diuretics (amiloride, triamterene)
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone, finerenone)
- ACE inhibitors (captopril, enalapril, lisinopril, benazepril)
- ARBs (losartan, valsartan, candesartan, telmisartan)
- Immunosuppressants (cyclosporine, tacrolimus) 7
The risk of hyperkalemia increases 8-fold when baxdrostat is combined with these agents 8. In clinical trials, hyperkalemia was the most frequent treatment-emergent adverse event 5.
Renal Function Considerations
Baxfendy can be used in patients with CKD, but requires careful monitoring. In a phase 2 trial of patients with CKD (mean baseline eGFR 44 mL/min/1.73 m²) and uncontrolled hypertension, baxdrostat reduced systolic BP by 8.1 mmHg (placebo-corrected) 5. However:
- Hyperkalemia occurred in 41% of baxdrostat-treated CKD patients versus 5% with placebo 5
- eGFR decreased modestly during treatment 6
- The FDA label addresses renal impairment considerations 1
For patients with moderate-to-severe renal impairment (eGFR <40 mL/min/1.73 m²), extra vigilance is warranted given the higher hyperkalemia risk demonstrated in the CKD trial 5.
Patient Selection
Baxfendy is indicated for adults with uncontrolled hypertension despite background antihypertensive therapy 1, 9. Clinical trials enrolled patients with:
- Uncontrolled hypertension: Seated SBP 140-170 mmHg on 2+ antihypertensives 3
- Resistant hypertension: Seated SBP 140-170 mmHg on 3+ antihypertensives including a diuretic 10, 3
The drug demonstrated consistent efficacy across both populations, with 24-hour ambulatory SBP reductions of 14.0 mmHg (placebo-corrected) in resistant hypertension 10.
Administration Instructions
Take Baxfendy orally once daily 1. The 2024 ESC guidelines recommend taking BP medications at the most convenient time for the patient to establish a habitual pattern and improve adherence 2, rather than mandating specific timing.
Safety Profile
Baxfendy is generally well-tolerated, but hyperkalemia is the primary safety concern requiring vigilant monitoring. 5, 3, 8
- Adverse events occurred in 52% of baxdrostat patients versus 37% with placebo 10
- Serious adverse events were not significantly increased 8, 11
- No deaths or adrenocortical insufficiency occurred in trials 4
- Potassium levels >6.0 mmol/L occurred in 2-3% of patients 3
Common Pitfalls to Avoid
- Do not combine with multiple potassium-retaining agents without intensive monitoring - the hyperkalemia risk multiplies 7, 5
- Do not skip baseline potassium and renal function testing - this is mandated by the FDA label 1
- Do not assume safety in advanced CKD - hyperkalemia rates reached 41% in CKD patients 5
- Do not use potassium-based salt substitutes - these contain 25-30% potassium chloride and are contraindicated with drugs that reduce potassium excretion 7